10:05 AM EDT, 10/20/2025 (MT Newswires) -- Palisade Bio ( PALI ) said Monday the first patients have been dosed in a phase 1b trial assessing PALI-2108 to treat fibrostenotic Crohn's disease.

Topline results are expected in Q1 2026, the company said.

The phase 1b trial will enroll about 6 to 12 patients with the disease, the company said, adding the trial is designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once a day oral dosing of the investigational drug during a 14-day period.

Results from the trial, plus data from the phase 1a/1b ulcerative colitis program, are expected to back phase 2 investigational new drug submissions to the US Food and Drug Administration in H1 2026, Palisade said.

Price: 1.79, Change: +0.05, Percent Change: +2.87